DNAnexus

Element Biosciences and DNAnexus® Announce Collaboration to Advance Multi-Omics Analysis

Retrieved on: 
Tuesday, February 6, 2024
Cloud, Transfer, SAN, Science, Research, Ecosystem, FASTQ, SVP, DNAnexus, Doctor of Philosophy, Element

SAN DIEGO, Feb. 6, 2024 /PRNewswire/ -- Element Biosciences, Inc., developer of pioneering technologies to empower science, announced a collaboration with DNAnexus, provider of the Precision Health Data Cloud, to allow customers to stream data from Element's AVITI™ System directly to their DNAnexus account. The collaboration combines the unmatched performance of AVITI sequencing with the secure and full-featured multi-omic analysis platform of DNAnexus.  The integration of AVITI with DNAnexus will be available to customers in Q1 2024.

Key Points: 
  • The collaboration combines the unmatched performance of AVITI sequencing with the secure and full-featured multi-omic analysis platform of DNAnexus.
  • "We are thrilled to have DNAnexus as a partner in the growing Element Biosciences analysis ecosystem," said Francisco Garcia, PhD, SVP of Informatics at Element Biosciences, speaking at the Advances in Genome Biology and Technology (AGBT) 2024 conference.
  • "This collaboration provides our customers with direct integration to DNAnexus' robust, flexible and user-friendly multi-modal analysis platform."
  • "Element Biosciences has established itself as a leading sequencing technology innovator and we are proud to join forces to help streamline multi-omics research."

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

Retrieved on: 
Wednesday, December 20, 2023
Myriad, HRD, Medicine, MYGN, Research, Fox Chase Cancer Center, MSI, Health, IRB, Genetics, Cancer, DNAnexus, TMB, Myriad Genetics, Institutional review board, Genetic testing, Patient, Microsatellite instability, MCRR, Pharmaceutical industry

SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).

Key Points: 
  • SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry ™ (MCRR).
  • The latest enhancements make the MCRR one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field.
  • Built on DNAnexus, a leading enterprise Precision Health platform, the MCRR provides a secure and easy-to-use interface for scientific data analysis, collaboration, and discovery.
  • Myriad is accepting research concept forms from individuals and institutions seeking to undertake research projects.

DNAnexus and Discovery Life Sciences to Streamline Precision Health Data Analysis

Retrieved on: 
Wednesday, December 13, 2023
Science, Biotechnology, Research, Health, Data Management, Health Technology, Technology, Genetics, Cloud, Privacy, Doctor of Philosophy, Clinical trial, Biological specimen, Infection, Genomics, Discovery, Cancer, Proteomics, Pharmaceutical industry, Medical device, DNAnexus

DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced a collaboration to help streamline Discovery’s next-generation sequencing data analysis.

Key Points: 
  • DNAnexus, Inc. , the provider of the Precision Health Data Cloud, and Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, today announced a collaboration to help streamline Discovery’s next-generation sequencing data analysis.
  • As part of the agreement, Discovery will use the DNAnexus cloud and analysis tools to optimize analysis pipeline performance, mitigate risk, and accelerate project turnaround times.
  • The purpose-built DNAnexus Precision Health Data Cloud provides Discovery with a flexible compute, storage, and collaboration environment to access and analyze multimodal data.
  • “This collaboration is another validation of the power of our Precision Health Data Cloud to harness the full potential of large-scale multimodal data and unlock insights that improve patient care.”

Fabric Genomics and DNAnexus Team Up to Improve Scale and Speed of Data Analysis for Genomic Medicine

Retrieved on: 
Wednesday, November 1, 2023
Software, Research, Networks, Internet, Pharmaceutical, Data Management, Technology, Genetics, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Health, Cloud, Genomics, Textile, Genetic distance, AUC, Doctor of Philosophy, Society, Multimedia, Data management, NGS, DNAnexus, DSM-IV codes, Partnership, Hospital, Privacy, AI, Patient, Medical device, Medical imaging, Antibiotics

View the full release here: https://www.businesswire.com/news/home/20231101812167/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231101812167/en/
    Through the partnership, Fabric Genomics will integrate its advanced genomic analysis tools and AI engine with the DNAnexus Precision Health Cloud, providing users with a push-button solution to move quickly from sample to evidence-backed analysis to actionable clinical reports.
  • “Through this collaboration with Fabric Genomics, we are enabling customers to unlock critical clinical insights hidden inside large-scale, genomic datasets,” said Thomas Laur, CEO at DNAnexus.
  • “The technology advances and cost reduction in genomics sequencing is generating an even larger data management and analysis bottleneck for clinical genomics labs.
  • Combining Fabric Genomics’ clinical expertise with the leading data management solution provided by DNAnexus, allows us to further clinical genomics,” said Martin Reese, PhD, CEO and co-founder of Fabric Genomics.

DNAnexus to Showcase the Power of the Precision Health Data Cloud at ASHG 2023 Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Research, Technology, Genetics, Software, Other Health, Biotechnology, Health, Data Management, Science, Other Science, Cloud, Privacy, ASHG, American Society of Human Genetics, Data divide, Society, Human genetics, Medical device, DNAnexus

DNAnexus, Inc. , the premier precision health data cloud provider, today announced the speaker lineup for its presentations at the American Society of Human Genetics (ASHG) Annual Meeting 2023 , which is being held in Washington, D.C., this week.

Key Points: 
  • DNAnexus, Inc. , the premier precision health data cloud provider, today announced the speaker lineup for its presentations at the American Society of Human Genetics (ASHG) Annual Meeting 2023 , which is being held in Washington, D.C., this week.
  • The company will be showcasing its Precision Health Data Cloud and large-scale analysis tools in booth #1802.
  • The DNAnexus Precision Health Data Cloud allows researchers to store, access, and explore large sets of proteomic, transcriptomic, genomic, phenotypic, imaging, and other structured data.
  • “DNAnexus has built the only secure and scalable Precision Health Data Cloud capable of managing, analyzing, and collaborating on large-scale multimodal biomedical datasets,” said Thomas Laur, CEO at DNAnexus.

PacBio Announces Complete Computational Workflow for Human Whole Genome Sequencing Data Analysis

Retrieved on: 
Wednesday, October 11, 2023
Cloud, Azure, DNAnexus, Methylation, Whole genome sequencing, Running, Google Cloud, Amazon Web Services, Abraxis BioScience, Workflow, WGS, AAV, High fidelity, Terra, Data analysis, GitHub, Mobile phone, Child, MD

MENLO PARK, Calif., Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis. The new software pipeline will enable customers to resolve many different variant types, including single-nucleotide polymorphisms, insertions and deletions, structural variants, tandem repeats, segmental duplications, and copy number variants, in addition to providing methylation and phasing data, all in a single bioinformatic solution – making it the most complete human WGS secondary analysis pipeline available. The single computational workflow integrates PacBio and third-party tools, including TRGT, Paraphase, and Google DeepVariant, in an intuitive user interface, offering customers a best-practice for HiFi WGS analysis.

Key Points: 
  • MENLO PARK, Calif., Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis.
  • The single computational workflow integrates PacBio and third-party tools, including TRGT , Paraphase , and Google DeepVariant, in an intuitive user interface, offering customers a best-practice for HiFi WGS analysis.
  • Previously, PacBio customers would need to use multiple bioinformatic tools to analyze HiFi data.
  • "Google is honored for DeepVariant to be included, and that PacBio and ourselves share the value of democratizing access to genome analysis at high accuracy."

DNAnexus-enabled UK Biobank Research Analysis Platform Surpasses 5,000 Users in Two Years

Retrieved on: 
Thursday, September 28, 2023
Research, Technology, Genetics, Software, Other Health, Biotechnology, Health, Data Management, Science, Other Science, PB, Biobank, UK Biobank, Cancer, Obesity, Global health, Data, Disease, Patient, Proteomics, UKB, Medical device, Pharmaceutical industry, DNAnexus

DNAnexus, Inc. , the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that the DNAnexus-enabled UK Biobank Research Analysis Platform (UKB-RAP) community has grown to more than 5,000 users around the world.

Key Points: 
  • DNAnexus, Inc. , the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that the DNAnexus-enabled UK Biobank Research Analysis Platform (UKB-RAP) community has grown to more than 5,000 users around the world.
  • Prior to the launch of the UKB-RAP, approved researchers had to download de-identified participant data to conduct their research analyses, requiring significant local storage space, computing power, and technical resources.
  • Later this year, it will also be the access point for the largest-ever whole-genome sequencing data release.
  • “The second year of the UKB-RAP has seen the platform and our community grow tremendously to more than 5,000 users,” said Dr. Mark Effingham, Deputy CEO of UK Biobank.

DNAnexus Announces Appointment of Thomas Laur as CEO

Retrieved on: 
Tuesday, September 12, 2023
Technology, Research, Genetics, Health Technology, Software, Biotechnology, Health, Data Management, Science, UnitedHealth Group, Health care, EVP, Change Healthcare, SAP, UNH, Optum, Growth, DNAnexus, NYSE, Management

Passing the CEO title to an exceptional leader like Thomas ensures our future success.”

Key Points: 
  • Passing the CEO title to an exceptional leader like Thomas ensures our future success.”
    Michael Goldberg, Executive Chair of the DNAnexus Board of Directors, commented: “Today’s announcement is the result of thoughtful succession planning.
  • Previously, Mr. Laur was President, Healthcare at SAP, holding end-to-end responsibility for the company’s global healthcare business.
  • Earlier in his career, Mr. Laur served as CEO at both Sutherland Healthcare Solutions and Cognizant Healthcare Ventures, where he focused on incubating new business models and scaling operations.
  • “At a time of accelerating innovation in multi-omics research and bioinformatics, I am honored to lead the next chapter at DNAnexus,” said Mr. Laur.

DNAnexus and BigOmics Analytics Join Forces to Improve Proteomics and Transcriptomics Data Visualization and Interpretation

Retrieved on: 
Wednesday, August 2, 2023
Health Technology, Data Management, Technology, Apps, Applications, General Health, Professional Services, Biometrics, Genetics, Biotechnology, Science, Software, Networks, Data Analytics, Internet, Research, Health, RNA-Seq, Organization, DNAnexus, Doctor of Philosophy, Proteomics, Data analysis, Environment, Playground, Privacy, Medicine, Medical device, Medical imaging

DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced a collaboration with BigOmics Analytics, a Swiss biomedical data analysis company.

Key Points: 
  • DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced a collaboration with BigOmics Analytics, a Swiss biomedical data analysis company.
  • As part of the agreement, BigOmics’ collaborative analysis environment, Omics Playground, is now available on the DNAnexus precision health data platform, providing customers with a fully integrated solution to better understand large-scale proteomics and transcriptomics data.
  • DNAnexus is the data cloud for precision health, allowing researchers to store, access, and explore large sets of proteomic, transcriptomic, genomic, phenotypic, imaging, and other structured data.
  • The Omics Playground platform offers an interactive interface with intuitive visualization and interpretation tools for exploring gene and protein expression activity patterns.

Fore Genomics Adopts DNAnexus Platform to Access and Analyze Whole-Genome Newborn Screening Data

Retrieved on: 
Tuesday, July 25, 2023
Data Management, Other Health, Technology, Pharmaceutical, General Health, Professional Services, Genetics, Baby, Maternity, Biotechnology, Science, Software, Other Science, Consumer, Data Analytics, Research, Health, NIST, Genetic variation, DNA, Genomics, Parent, ISO27001, Privacy, Risk, Map, Genetic testing, GDPR, Fore, DNAnexus, Gene, Disease, Antibiotics

DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test.

Key Points: 
  • DNAnexus Inc., the leading provider of cloud-based genomic and biomedical data access and companion analysis software, today announced that Fore Genomics, a proactive genetic testing company designed for healthy newborns, infants, and children, is using the DNAnexus platform for its FORESITE 360 test.
  • The purpose-built and scalable DNAnexus platform enables Fore Genomics to meet with current and future security, quality, and compliance requirements as they evolve over time.
  • The FORESITE 360 test is a groundbreaking health information service that creates a complete genomic profile using a baby’s DNA.
  • “Protecting our customer data is paramount to what we do, and DNAnexus offers the industry's most stringent security, privacy, and compliance platform.